10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Mirador Capital Partners LP

Mirador Capital Partners LP grew its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 39.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 80,983 shares of the company’s stock after buying an additional 22,792 shares during the quarter. Mirador Capital Partners LP’s holdings in 10x Genomics were worth $1,163,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of TXG. GAMMA Investing LLC increased its holdings in shares of 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after buying an additional 1,265 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in 10x Genomics in the 3rd quarter valued at approximately $35,000. Blue Trust Inc. boosted its position in 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after buying an additional 1,025 shares during the period. Sound Income Strategies LLC purchased a new position in 10x Genomics in the 3rd quarter valued at approximately $46,000. Finally, Venturi Wealth Management LLC boosted its position in 10x Genomics by 1,108.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after buying an additional 2,240 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Stock Performance

Shares of TXG opened at $14.67 on Thursday. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -9.59 and a beta of 1.83. 10x Genomics, Inc. has a 1 year low of $12.95 and a 1 year high of $51.22. The company’s 50 day simple moving average is $15.02 and its 200 day simple moving average is $18.02.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. The company had revenue of $151.65 million for the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. 10x Genomics’s revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.51) earnings per share. Equities analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TXG shares. Morgan Stanley decreased their price target on shares of 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday. Stephens reissued an “overweight” rating and issued a $30.00 price target on shares of 10x Genomics in a research report on Thursday, October 10th. JPMorgan Chase & Co. reduced their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. The Goldman Sachs Group reduced their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a report on Wednesday, October 30th. Finally, Citigroup cut their price target on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.86.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.